Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FINPROVE targeted therapy basket study for advanced cancers
2024-517478-68-01Phase 2Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abemaciclib, atezolizumab, alectinib, vismodegib, ponatinib and 12 more in cancer, sponsored by Helsinki University Hospital. Primary endpoint: Disease control rate at 16 weeks. Planned start Nov 2024; status: authorised.
02
Drugs
abemaciclibatezolizumabalectinibvismodegibponatinib
03
Conditions
cancer
Beyond the preview
Go deeper on 2024-517478-68-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517478-68-01.